Get the Stockscreener App
16.42
1.97%
-0.33
After Hours:
16.40
-0.02
-0.12%
Sarepta Therapeutics Inc stock is traded at $16.42, with a volume of 14.14M.
It is down -1.97% in the last 24 hours and down -3.98% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$16.75
Open:
$16.49
24h Volume:
14.14M
Relative Volume:
1.39
Market Cap:
$1.61B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-6.1041
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
+27.48%
1M Performance:
-3.98%
6M Performance:
-85.56%
1Y Performance:
-88.46%
1-Day Range:
$16.11
$17.58
1-Week Range:
$11.12
$19.24
52-Week Range:
$10.41
$145.00
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
16.42 | 1.65B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Roche Slammed With Negative EMA CHMP Opinion for Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action PendingHagens Berman - PR Newswire
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results - The Globe and Mail
Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky Before August 25, 2025 - ACCESS Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Sarepta Therapeutics (NASDAQ:SRPT) Sees Strong Trading Volume on Analyst Upgrade - Defense World
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - Defense World
FDA Gives Sarepta Green Light to Restart Shipment of DMD Gene Therapy Elevidys to Patients who are Ambulatory - CGTLive®
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, - GlobeNewswire
SRPT INVESTOR NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors to Contact the Firm before the Imminent August 25 Class Action Deadline - Newsfile
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - ACCESS Newswire
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient - GlobeNewswire
Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdles - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by Barclays to “Equal Weight” Rating - Defense World
FDA’s Prasad Exits Following Political Backlash Over Sarepta - Bloomberg
FDA’s Prasad Exits Following Political Backlash Over Sarepta (3) - Bloomberg Law News
FDA vaccines head, chief medical officer Vinay Prasad departs agency - Seeking Alpha
Sarepta Therapeutics stock price target raised to $19 from $14 at Mizuho - Investing.com
Stocks making the biggest moves midday: Harley-Davidson, Wingstop, Sarepta Therapeutics and more - CNBC
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
Sarepta, other Mass. biotech stocks rise on Prasad’s FDA exit - The Business Journals
Sarepta stock, Replimmune stock up as FDA’s biologics head exits - Seeking Alpha
US FDA's top vaccine official Vinay Prasad leaves agency after short stint - Reuters
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy - Fierce Pharma
Sarepta gene therapy deaths highlight tragic rare disease dilemma - Chemistry World
Why SRPT Stock Surged 48%? - timothysykes.com
Sarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at Morgan Stanley - Defense World
Bernstein raises Sarepta Therapeutics stock price target to $18 on Elevidys - Investing.com
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by JPMorgan Chase & Co. to “Neutral” Rating - Defense World
SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - GlobeNewswire
Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to Equal Weight - Defense World
Sarepta Therapeutics (SRPT) Faces Renewed Scrutiny After ELEVIDYS Linked Safety Events and Legal Challenges - simplywall.st
Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy - Mint
Is Sarepta Therapeutics Inc. forming a reversal patternFree Exit Ready Momentum Stock Watchlist - Newser
Sarepta Therapeutics’ (SRPT) Outperform Rating Reaffirmed at William Blair - Defense World
Sarepta Therapeutics (SRPT) Faces FDA Challenges Amid Executive Departure - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Outperform at Oppenheimer - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given New $15.00 Price Target at Piper Sandler - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright - Defense World
Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use - TipRanks
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade - Defense World
Sarepta soars after FDA says some patients can get Elevidys - The Boston Globe
Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments - Investor's Business Daily
Sarepta Therapeutics, Inc. (SRPT): “You Don’t Court Homicide,” Says Jim Cramer - Yahoo Finance
Sarepta Stock On the Rise Following Resumption of Elevidys Shipments in US - PharmExec
Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault. - MSN
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys - Stocktwits
Market movers: PayPal, Sarepta Therapeutics, UnitedHealth... - Proactive financial news
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):